Alnylam Pharmaceuticals reported $30.26M in Cost of Sales for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US $ 5.21M 0.51M
Alexion Pharmaceuticals ALXN:US $ 125.4M 26.8M
Alnylam Pharmaceuticals ALNY:US $ 30.26M 7.23M
Amgen AMGN:US $ 1637M 147M
Biocryst Pharmaceuticals BCRX:US $ 0.34M 5.54M
Biomarin Pharmaceutical BMRN:US $ 127.06M 6.9M
Bluebird Bio BLUE:US $ 15.3M 13.02M
Gw Pharmaceuticals GWPH:US $ 11.81M 1.39M
Intercept Pharmaceuticals ICPT:US $ 0.62M 0.19M
IONIS PHARMACEUT IONS:US $ 2.96M 0.38M
Moderna Inc MRNA:US 750M 557M
Neurocrine Biosciences NBIX:US $ 3.1M 0.2M
Novartis NVS:US $ 3754M 79M
Ptc Therapeutics PTCT:US $ 7.36M 1.75M
Regeneron Pharmaceuticals REGN:US $ 693.7M 385.7M
Sarepta Therapeutics SRPT:US $ 19.52M 2.83M
Takeda 4502:JP Y 241264M 12182M
Ultragenyx Pharmaceutical RARE:US $ 3.14M 2.05M
Vertex Pharmaceuticals VRTX:US $ 227.97M 35.64M
YTE INCY:US $ 32.63M 8.81M